AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 328209 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 328209 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 31291491 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound thalamotomy
Number of subjects: 62
Study 31291491 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 62
Study 31291491 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound subthalamotomy
Number of subjects: 62
Study 31291491 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound pallidotomy
Number of subjects: 62
Study 28574528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting of etiquette behaviors every 2 weeks for 12 months
Number of subjects: 0
Study 28574528 — intervention group
Group type: COMPARATOR
Intervention: Control arm received questions on quality improvement behaviors
Number of subjects: 0
Study 25271354 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and moxonidine (group VM)
Number of subjects: 42
Study 25271354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide and amlodipine (group BA)
Number of subjects: 42
Study 25271354 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age-matched)
Number of subjects: 42
Study 23782814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib
Number of subjects: 451
Study 23782814 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 451
Study 23782814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (in patients with activating EGFR gene mutation)
Number of subjects: 451
Study 23782814 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo (in patients with activating EGFR gene mutation)
Number of subjects: 451
Study 22151975 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800 IU of vitamin D and 1000 mg of calcium daily)
Number of subjects: 704
Study 22151975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 19427094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric laparoscopic assisted minilaparotomy myomectomy (LM)
Number of subjects: 80
Study 19427094 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy (MLT)
Number of subjects: 80
Study 16989901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (32 mg/day)
Number of subjects: 685
Study 16989901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 14627173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dosing with budesonide/formoterol (Symbicort, Turbuhaler) 80/4.5 microg or 160/4.5 microg, two inhalations twice daily for four weeks, followed by adjustable maintenance dosing for six months
Number of subjects: 1034
Study 14627173 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing with budesonide/formoterol (Symbicort, Turbuhaler)
Number of subjects: 1034
Study 16212331 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy only (MDO)
Number of subjects: 125
Study 16212331 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy followed by autologous bone graft (ABG)
Number of subjects: 125
Study 16212331 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy followed by polymethylmethacrylate (PMMA)
Number of subjects: 125
Study 16212331 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy followed by threaded titanium cage (TTC)
Number of subjects: 125
Study 9703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 45
Study 9703286 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 45
Study 9173128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (15,000 units)
Number of subjects: 3540
Study 9173128 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 3540
Study 2915651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (six cycles of cyclophosphamide 100 mg/m² orally on days 1-14, methotrexate 40 mg/m² intravenously on days 1 and 8, fluorouracil 600 mg/m² intravenously on days 1 and 8, and prednisone 40 mg/m² orally on days 1-14)
Number of subjects: 536
Study 2915651 — intervention group
Group type: COMPARATOR
Intervention: No-treatment observation (Control)
Number of subjects: 536
Study 2915651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 536
Study 951456 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine formulations
Number of subjects: 0
Study 30817402 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell transfusion threshold (7 g/dl)
Number of subjects: 0
Study 30817402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma and platelets during burn excision
Number of subjects: 0
Study 30817402 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion practice during burn excision and grafting
Number of subjects: 0
Study 29390308 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 611
Study 29390308 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 611
Study 29390308 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 611
Study 24983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay mesh augmentation (OMA)
Number of subjects: 480
Study 24983993 — intervention group
Group type: COMPARATOR
Intervention: Primary suture
Number of subjects: 480
Study 24983993 — intervention group
Group type: COMPARATOR
Intervention: Sublay mesh augmentation
Number of subjects: 480
Study 23571642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary foot-care program (12 months, involving a paediatric rheumatologist, podiatrist, physiotherapist, and musculoskeletal ultrasonographer)
Number of subjects: 44
Study 23571642 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (usual care)
Number of subjects: 44
Study 22052161 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative learning method
Number of subjects: 146
Study 22052161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualistic learning method
Number of subjects: 146
Study 22052161 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (both methods)
Number of subjects: 146
Study 22052161 — intervention group
Group type: COMPARATOR
Intervention: Collaborative vs Individualistic learning
Number of subjects: 146
Study 19352162 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (10 ml, 1%)
Number of subjects: 60
Study 19352162 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 60
Study 16672092 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop group (propofol titration using a proportional differential algorithm)
Number of subjects: 40
Study 16672092 — intervention group
Group type: COMPARATOR
Intervention: Target control infusion (TCI) group (manual propofol titration guided by Bispectral Index using Diprifusor device)
Number of subjects: 40
Study 14754826 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention designed to encourage graded activity
Number of subjects: 114
Study 14754826 — intervention group
Group type: COMPARATOR
Intervention: Control group (initially not receiving the intervention)
Number of subjects: 114
Study 11358728 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 0
Study 11358728 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0
Study 11358728 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 0
Study 11358728 — intervention group
Group type: COMPARATOR
Intervention: Tacalcitol
Number of subjects: 0
Study 11358728 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 0
Study 9143797 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Wear (EW)
Number of subjects: 134
Study 9143797 — intervention group
Group type: COMPARATOR
Intervention: Daily Wear (DW)
Number of subjects: 134
Study 29510425 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut ball device
Number of subjects: 96
Study 29510425 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 29510425 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut ball device (subgroup with labor arrest)
Number of subjects: 96
Study 29510425 — intervention group
Group type: COMPARATOR
Intervention: Usual care (subgroup with labor arrest)
Number of subjects: 96
Study 27118225 — intervention group
Group type: EXPERIMENTAL
Intervention: HFPEF
Number of subjects: 90
Study 25447749 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) with cathode-right
Number of subjects: 4
Study 25447749 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) with cathode-left
Number of subjects: 4
Study 25447749 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study 23845729 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric‐eccentric‐isometric contractions
Number of subjects: 13
Study 23845729 — intervention group
Group type: EXPERIMENTAL
Intervention: Purely isometric contractions
Number of subjects: 13
Study 19392925 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 13110
Study 19392925 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 13110
Study 19392925 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 13110
Study 19392925 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg
Number of subjects: 13110
Study 19392925 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 16 mg
Number of subjects: 13110
Study 17219280 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral internal sphincterotomy
Number of subjects: 50
Study 17219280 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 50
Study 15499528 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1204 (10^7, 10^8, or 10^9 cfu)
Number of subjects: 44
Study 15499528 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208 (10^7, 10^8, or 10^9 cfu)
Number of subjects: 44
Study 15499528 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1204
Number of subjects: 44
Study 15499528 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208
Number of subjects: 44
Study 11794731 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat conditioning before induction of hyperalgesia (45 degrees C for 5 min)
Number of subjects: 0
Study 11794731 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat conditioning after induction of hyperalgesia (2 degrees C above individual pain threshold)
Number of subjects: 0
Study 11794731 — intervention group
Group type: COMPARATOR
Intervention: No heat conditioning (control)
Number of subjects: 0
Study 9484362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) during rIFN beta‐1a treatment
Number of subjects: 29
Study 9484362 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) without rIFN beta‐1a treatment
Number of subjects: 29
Study 8038592 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF, interferon‐gamma (IFN‐gamma), and melphalan
Number of subjects: 0
Study 8038592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TNF in isolated limb perfusions
Number of subjects: 0
Study 8038592 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF, IFN, and melphalan limb perfusion with systemic high-dose interleukin-2 postoperatively
Number of subjects: 0
Study 8038592 — intervention group
Group type: COMPARATOR
Intervention: Standard melphalan-alone perfusion
Number of subjects: 0
Study 2924980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 8 days
Number of subjects: 10
Study 2924980 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg daily for 8 days
Number of subjects: 10
Study 241876 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (50 mg three times daily for 4 weeks)
Number of subjects: 8
Study 241876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times daily)
Number of subjects: 8
Study 30353406 — intervention group
Group type: EXPERIMENTAL
Intervention: Early NG tube removal (removed on postoperative day 1)
Number of subjects: 80
Study 30353406 — intervention group
Group type: COMPARATOR
Intervention: Conventional NG tube removal (removed on postoperative day 7)
Number of subjects: 80
Study 30353406 — intervention group
Group type: EXPERIMENTAL
Intervention: Early NG tube removal
Number of subjects: 80
Study 30353406 — intervention group
Group type: COMPARATOR
Intervention: Conventional NG tube removal
Number of subjects: 80
Study 28646182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 45
Study 28646182 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 45
Study 28646182 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 45
Study 26314605 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace WetBond sealant
Number of subjects: 34
Study 26314605 — intervention group
Group type: COMPARATOR
Intervention: Helioseal sealant
Number of subjects: 34
Study 23448100 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 3000
Study 23448100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Tailored intervention
Number of subjects: 3000
Study 23448100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3000
Study 21320087 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Fastrach
Number of subjects: 154
Study 21320087 — intervention group
Group type: COMPARATOR
Intervention: Air-Q
Number of subjects: 154
Study 17932248 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate therapy
Number of subjects: 454
Study 17870476 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 75
Study 17870476 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined position (45 degrees)
Number of subjects: 75
Study 17870476 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position (90 degrees)
Number of subjects: 75
Study 15118645 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester ultrasound screening
Number of subjects: 218
Study 15118645 — intervention group
Group type: COMPARATOR
Intervention: Second trimester ultrasound screening
Number of subjects: 218
Study 11673142 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 0
Study 11673142 — intervention group
Group type: COMPARATOR
Intervention: Cold Steel Scalpel (CSS)
Number of subjects: 0
Study 9196522 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum
Number of subjects: 16
Study 9196522 — intervention group
Group type: COMPARATOR
Intervention: Bronchial washings
Number of subjects: 16
Study 9196522 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL) fluid
Number of subjects: 16
Study 7835803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 7835803 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus a platinum compound
Number of subjects: 0
Study 3323072 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline (10 mg/day) and metoprolol (200 mg/day)
Number of subjects: 36
Study 3323072 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (200 mg/day) alone
Number of subjects: 36
Study 3323072 — intervention group
Group type: COMPARATOR
Intervention: terbutaline (10 mg/day) alone
Number of subjects: 36
Study 31362066 — intervention group
Group type: COMPARATOR
Intervention: Control group with additional follow-up assessments
Number of subjects: 516
Study 30896618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 918
Study 30896618 — intervention group
Group type: COMPARATOR
Intervention: Preserved renal function
Number of subjects: 918
Study 30896618 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD with LVEF <50%
Number of subjects: 918
Study 30896618 — intervention group
Group type: COMPARATOR
Intervention: Preserved renal function with LVEF <50%
Number of subjects: 918
Study 30896618 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD
Number of subjects: 918
Study 27922921 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation and therapeutic walking for 3 months
Number of subjects: 87
Study 27922921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 25912899 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing with intrinsic pacing (BiV + intrinsic pacing)
Number of subjects: 44
Study 23910665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 600 mg/d for 7 days
Number of subjects: 88
Study 23910665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/d for 7 days
Number of subjects: 88
Study 23910665 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg on day 7
Number of subjects: 88
Study 23910665 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 88
Study 21270330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normoglycemia
Number of subjects: 0
Study 21270330 — intervention group
Group type: COMPARATOR
Intervention: Tolerating excessive hyperglycemia
Number of subjects: 0
Study 19449244 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letter fluency test (2 minutes per trial)
Number of subjects: 60
Study 19449244 — intervention group
Group type: COMPARATOR
Intervention: Standard letter fluency test (1 minute per trial)
Number of subjects: 60
Study 16458451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose levamisole (LMS)
Number of subjects: 0
Study 16458451 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 15078039 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked repetition priming with a prime validity of 0.8 (high proportion of trials with repetition primes)
Number of subjects: 0
Study 15078039 — intervention group
Group type: COMPARATOR
Intervention: Masked repetition priming with a prime validity of 0.2 (low proportion of trials with repetition primes)
Number of subjects: 0
Study 11478456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 ug/kg body weight, 2 doses, 3 months apart)
Number of subjects: 73
Study 11478456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 73
Study 9757894 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of the diameter of the external cervical os
Number of subjects: 25
Study 7872409 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-based attention hypothesis
Number of subjects: 0
Study 7872409 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-based retrieval hypothesis
Number of subjects: 0
Study 3045069 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with vidarabine sodium phosphate in an aqueous gel
Number of subjects: 134
Study 3045069 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 134
Study 30721647 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session, clinic-based intervention promoting condom use
Number of subjects: 277
Study 30721647 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 277
Study 29686147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 1066
Study 29686147 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 1066
Study 27145159 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial electromechanical conduction time (EMT‐ε) measured with speckle tracking echocardiography after pulmonary vein isolation (PVI)
Number of subjects: 46
Study 27145159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 46
Study 27145159 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT‐ε shortening at 6 months after PVI
Number of subjects: 46
Study 27145159 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (10 subjects)
Number of subjects: 46
Study 24205991 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-cyclodextrin nanoparticle eye drops containing 3% dorzolamide, given once a day (QD)
Number of subjects: 17
Study 24205991 — intervention group
Group type: COMPARATOR
Intervention: Trusopt given three times a day (TID)
Number of subjects: 17
Study 22998554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention
Number of subjects: 62
Study 22998554 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 20631014 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (1‐34) for 14 days
Number of subjects: 27
Study 20631014 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 17610013 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged stage transition duration (STD) in aspirating stroke patients
Number of subjects: 66
Study 17610013 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged stage transition duration (STD)
Number of subjects: 66
Study 17610013 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirating stroke participants
Number of subjects: 66
Study 16111499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 9795
Study 16111499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study 12501952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic AFOs
Number of subjects: 14
Study 12501952 — intervention group
Group type: EXPERIMENTAL
Intervention: Static AFOs
Number of subjects: 14
Study 12501952 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 14
Study 9703563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg papaverine
Number of subjects: 56